Lobular Breast Cancer can be more difficult to see on imaging and scans. It can be harder to detect on mammograms, resulting in later-stage diagnosis […]
Expert Opinion: Imaging and Lobular Breast Cancer Read More »
The Lobular Breast Cancer Alliance sent six patient research advocates to the San Antonio Breast Cancer Symposium (SABCS) in December, 2018 and compiled highlights and
ILC Research at SABCS 2018 Read More »
by LBCA Steering Committee member Diane Mapes (aka @double_whammied) Report from ASCO 2019:Â Q & A with Dr. Otto Metzger The 2019 annual meeting of the
Interview: Study highlights differences in Pre-menopausal ILC/IDC Read More »
Study indicates oncoplastic and shave margin surgical techniques for ILC mastectomies reduce repeated surgeries for lobular breast cancer (ILC)
Study: Beneficial Surgical Techniques for ILC Lumpectomies Read More »
The ROLO trial is a targeted therapy clinical trial in the United Kingdom for patients with advanced or metastatic lobular breast cancer. Name of the
ROLO: Targeted Therapy Trial for Advanced ILC Read More »
The GELATO clinical trial was a lobular breast-cancer specific immunotherapy trial investigating the response to an immunotherapy + chemotherapy medication combination. This phase 2 trial
GELATO: Immunotherapy Clinical Trial for ILC Mets Read More »
Women who have been diagnosed with Stage 1 – 3 invasive lobular breast cancer (ILC) who have not yet had surgery to remove their tumor may be eligible to participate in a clinical trial. This trial is open to all ER+ and/or PR+ HER2- patients (ductal or lobular), however it is being enriched with lobular breast cancer patients to promote a better understanding of how ILC might respond differently to these therapies.
PELOPS: Clinical Trial with Palbociclib for Pre-surgical ILC Patients Read More »
Excerpt below. Read the full article from the Fred Hutch News Service or Download and Share a printable .pdf. Lobular breast cancer comes into the spotlight
IN THE NEWS: Lobular Breast Cancer Comes into the Spotlight Read More »
The European School of Oncology (ESO) offered an e-learning session on November 10, 2018 focusing on treatment of early-stage lobular breast cancer. The session entitled Treatment of
European School of Oncology: Treatment for early stage ILC Read More »
Patient advocates identify opportunities to improve patient outcomes and care
Mini-Symposium:Â Lobular Breast Cancer: Is it a Different Disease and LBCA Poster Presentation
Video: ILC Mini-Symposium at 2017 San Antonio Breast Cancer Symposium Read More »
Materials from the First Lobular Breast Cancer Symposium, Pittsburgh Sept 2016
First International Invasive Lobular Breast Cancer Symposium (2016) Read More »
Lobular Breast Cancer Alliance Inc. (LBCA) is a Delaware nonprofit corporation that is registered as a 501(c)(3) public charity. Tax ID Number: 86-2260246. Donations to LBCA are tax-deductible. to the fullest extent allowed by applicable law.
© 2024 The Lobular Breast Cancer Alliance Inc. | Privacy Policy | Terms of Use | State Fundraising Notices
Site by SuzanneHarrisonWeb.com
"*" indicates required fields